Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: Investigation in the QUASAR2 study, systematic review, and meta-analysis.

Rosmarin, D; Palles, C; Church, D; Domingo, E; Jones, A; Johnstone, E; Wang, H; Love, S; Julier, P; Scudder, C; Nicholson, G; Gonzalez-Neira, A; Martin, M; Sargent, D; Green, E; McLeod, H; Zanger, U; Schwab, M; Braun, Michael S; Seymour, M; Thompson, L; Lacas, B; Boige, V; Ribelles, N; Afzal, S; Enghusen, H; Astrup Jensen, S; Etienne-Grimaldi, M; Milano, G; Wadelius, M; Glimelius, B; Garmo, H; Gusella, M; Lecomte, T; Laurent-Puig, P; Martinez-Balibrea, E; Sharma, R; Garcia-Foncillas, J; Kleibl, Z; Morel, A; Pignon, J; Midgley, R; Kerr, D; Tomlinson, I

Affiliation

Wellcome Trust Centre for Human Genetics, NIHR Comprehensive Biomedical Research Centre, University of Oxford

Issue Date

2014-03-03

Metadata

Show full item record

Abstract

Fluourouracil (FU) is a mainstay of chemotherapy, although toxicities are common. Genetic biomarkers have been used to predict these adverse events, but their utility is uncertain.

Citation

Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis. 2014: J Clin Oncol

Journal

Journal of Clinical Oncology

URI

http://hdl.handle.net/10541/314897

DOI

10.1200/JCO.2013.51.1857

PubMed ID

24590654

Type

Article

Language

ISSN

1527-7755

Collections

All Christie Publications